Research Article
Improved Survival Outcome and Access to Cancer Screening from Hemorrhoid in Patients with Rectal Cancer
Table 1
Distribution of baseline characteristics between patients with and without previous history of hemorrhoid.
| | Characteristic | Overall population | Previous history of hemorrhoid | value | | No | Yes | | () | () | () |
| | Age-yr, median (range) | 59 (21-89) | 59 (21-89) | 61 (33-77) | 0.942 | | BMI, median (range) | 22.1 (13.3-35.9) | 22.1 (13.3-35.9) | 22.4 (16.6-30.3) | 0.971 | | Sex | | | | 0.533 | | Male | 295 (57.8) | 267 (57.4) | 28 (62.2) | | | Female | 215 (42.2) | 198 (42.6) | 17 (37.8) | | | Patient-reported symptoms | | | | | | Blood stools | 352 (69.0) | 318 (68.4) | 34 (75.6) | 0.321 | | Bowel habits change | 110 (21.6) | 101 (21.7) | 9 (20.0) | 0.789 | | Stools shape change | 65 (12.7) | 59 (12.7) | 6 (13.3) | 0.901 | | Abdominal pain | 36 (7.1) | 32 (6.9) | 4 (8.9) | 0.616 | | Time to symptom onset | | | | 0.964 | | 0-6 months | 348 (69.2) | 317 (69.2) | 31 (68.9) | | | >6 months | 155 (30.8) | 141 (30.8) | 14 (31.1) | | | Tumor location: distance from anal verge | | | 0.453 | | 0-5 cm | 207 (38.5) | 192 (39.0) | 15 (33.3) | | | 5-12 cm | 330 (61.5) | 300 (61.0) | 30 (66.7) | | | Tumor location: orientation | | | | | Anterior wall | 72 (14.1) | 66 (14.2) | 6 (13.3) | 0.874 | | Posterior wall | 86 (16.9) | 83 (17.8) | 3 (6.7) | 0.056 | | Lateral wall | 45 (8.8) | 38 (8.2) | 7 (15.6) | 0.101 | | Circumferential | 124 (24.3) | 112 (24.1) | 12 (26.7) | 0.700 | | TNM stage, AJCC | | | | 0.049 | | I-II | 292 (57.3) | 260 (55.9) | 32 (71.1) | | | III | 218 (42.7) | 205 (44.1) | 13 (28.9) | | | T stage | | | | 0.100 | | T1-2 | 160 (31.4) | 141 (30.3) | 19 (42.2) | | | T3-4 | 350 (68.6) | 324 (69.7) | 26 (57.8) | | | Differentiation degree | | | | 0.192 | | Low | 94 (19.1) | 89 (19.8) | 5 (11.6) | | | Moderate/high | 398 (80.9) | 360 (80.2) | 38 (88.4) | | | Lymphovascular invasion | | | | 0.787 | | Negative | 463 (90.8) | 421 (90.5) | 42 (93.3) | | | Positive | 47 (9.2) | 44 (9.5) | 3 (6.7) | | | Perineural invasion | | | | 0.109 | | Negative | 460 (90.2) | 416 (89.5) | 44 (97.8) | | | Positive | 50 (9.8) | 49 (10.5) | 1 (2.2) | | | Preoperative CEA | | | | 0.849 | | 0-5 ng/mL | 327 (69.4) | 298 (69.3) | 29 (70.7) | | | >5 ng/mL | 144 (30.6) | 132 (30.7) | 12 (29.3) | | | Preoperative neutrophil-to-lymphocyte ratio | | | 0.620 | | <3 | 389 (78.9) | 353 (78.6) | 36 (81.8) | | | >/=3 | 104 (21.1) | 96 (21.4) | 8 (18.2) | | | Preoperative platelet-to-lymphocyte ratio | | | 0.732 | | 0-100 | 147 (29.5) | 135 (29.7) | 12 (27.3) | | | >100 | 351 (70.5) | 319 (70.3) | 32 (72.7) | | | Adjuvant treatment | | | | 0.305 | | No | 228 (46.1) | 204 (45.3) | 24 (53.3) | | | Yes | 267 (53.9) | 246 (54.7) | 21 (46.7) | | | Neoadjuvant treatment | | | | 0.060 | | No | 432 (86.4) | 389 (85.5) | 43 (95.6) | | | Yes | 68 (13.6) | 66 (14.5) | 2 (4.4) | |
|
|
BMI: body mass index; CEA: carcinoembryonic antigen.
|
